Trial Profile
Virological and Immunological Safety of a Dose Reduction Strategy Antiretroviral Regimen With Efavirenz / Tenofovir / Emtricitabine
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Efavirenz/emtricitabine/tenofovir-disoproxil-fumarate (Primary)
- Indications HIV-1 infections
- Focus Proof of concept; Therapeutic Use
- Acronyms A-TRI-WEEK
- 01 May 2019 Results published in the AIDS
- 09 May 2018 Results published in the AIDS
- 01 Sep 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.